MIR148B

Summary

MIR148B (microRNA 148b, HGNC:31761) is a microRNA gene on chromosome 12q13.13.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 442892 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31761
Approved symbol	MIR148B
Name	microRNA 148b
Location	12q13.13
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-148b
Ensembl gene	ENSG00000199122
Ensembl biotype	miRNA
OMIM	613787
Entrez	442892
RNAcentral	URS000075C16C — miRNA, 99 nt, 16 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000362252

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000362252 — 1 exons

Exon	Start	End
ENSE00001437015	54337216	54337314

Expression profiles

Bgee: expression breadth broad, 76 present calls, max score 79.17.

Top tissues by expression

76 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	79.17	gold quality
kidney	UBERON:0002113	78.71	gold quality
muscle of leg	UBERON:0001383	77.34	gold quality
adrenal tissue	UBERON:0018303	76.67	gold quality
monocyte	CL:0000576	76.31	gold quality
liver	UBERON:0002107	75.54	gold quality
endometrium	UBERON:0001295	75.40	gold quality
adult mammalian kidney	UBERON:0000082	75.28	gold quality
gastrocnemius	UBERON:0001388	75.21	gold quality
bone marrow	UBERON:0002371	74.46	gold quality
body of pancreas	UBERON:0001150	73.23	gold quality
stomach	UBERON:0000945	73.02	gold quality
body of stomach	UBERON:0001161	71.94	gold quality
heart	UBERON:0000948	71.91	gold quality
heart left ventricle	UBERON:0002084	71.60	gold quality
calcaneal tendon	UBERON:0003701	70.80	gold quality
right atrium auricular region	UBERON:0006631	70.56	gold quality
right adrenal gland cortex	UBERON:0035827	70.25	gold quality
lung	UBERON:0002048	70.02	gold quality
right adrenal gland	UBERON:0001233	69.77	gold quality
left adrenal gland	UBERON:0001234	69.74	gold quality
intestine	UBERON:0000160	69.51	gold quality
lower esophagus muscularis layer	UBERON:0035833	69.29	gold quality
ascending aorta	UBERON:0001496	69.25	gold quality
colon	UBERON:0001155	69.14	gold quality
ovary	UBERON:0000992	68.50	gold quality
right frontal lobe	UBERON:0002810	68.24	gold quality
transverse colon	UBERON:0001157	68.20	gold quality
Brodmann (1909) area 9	UBERON:0013540	68.18	gold quality
left ovary	UBERON:0002119	68.12	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.65

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• miR-148b acts as a tumor suppressor in gastric cancer (PMID:21205300)
• Loss of MicroRNA-148b is associated with upregulation of cholecystokinin-2 receptor resulting in colorectal cancer. (PMID:22020560)
• miR-148b may be involved in the early stage of ovarian carcinogenesis and could be used as an ef fi cient diagnostic biomarker. (PMID:22344713)
• data suggest a role for miRNAs in the pathogenesis of IgA nephropathy. Abnormal expression of miR-148b may explain the aberrant glycosylation of IgA1, providing a potential pharmacologic target for IgA nephropathy (PMID:22362909)
• miR-148b plays an important role in the response of non-Hodgkin’s Lymphoma to ionizing radiation (PMID:22843616)
• Upregulation of plasma MIR148B is associated with breast cancer. (PMID:22927033)
• miR-148b can inhibit cell proliferation, invasion, and enhance chemosensitivity of pancreatic cancer by targeting AMPKalpha1. (PMID:23171948)
• miR-148b controls malignancy by coordinating a novel pathway involving over 130 genes and, in particular, it directly targets players of the integrin signaling, such as ITGA5, ROCK1, PIK3CA/p110alpha, and NRAS, as well as CSF1 (PMID:23233531)
• Data show that TLR3 activation by poly I-C induces up-regulation of microRNA-29b, -29c, -148b, and -152 targeting DNA methyltransferases, leading to demethylation and reexpression of the oncosuppressor retinoic acid receptor beta (RARbeta). (PMID:23716670)
• miRs that are targeting DNMT-1 and modifying methylation status of tumor suppressor genes such as BNIP3 and SPARC can be applied in killing the pancreatic cancer cells and decreasing the tumorigenicity of these cells. (PMID:24448385)
• study shows that the p53/miR-148b/p55PIK axis has an important role in cell proliferation and tumor growth, and may represent a novel therapeutic target for treating cancers containing p53 mutations or losses. (PMID:24632606)
• miR-148b expression was decreased in hepatocellular carcinoma patients and associated with tumor progression. (PMID:24805877)
• microRNA-148b was downregulated in circulating peripheral blood mononuclear cells in chronic myeloid leukemia patients with undetectable minimal residual disease (PMID:25187697)
• Serum miR-148a, miR-148b, and miR-152 were significantly downregulated in NSCLC patients. The combination of four candidate miRNAs exhibited the highest predictive accuracy in non-small cell lung cancer screening compared (PMID:25501703)
• WNT1 was a direct target of miR-148b, and overexpressed WNT1 inversely correlated with miR-148b levels in hepatocellular carcinoma tissues. (PMID:25627001)
• For selected miRNAs, namely miR-149, miR-148b, miR-326, and miR-520a-3p, we demonstrate the simultaneous downregulation of the ErbB3 receptor and multiple downstream signaling molecules. (PMID:25630670)
• our data indicate that decreased expression of miR-148b in non-small cell lung cancer tissues has prognostic value. (PMID:25755777)
• relative expression levels of miR-148/152 family (miR-148a, miR-148b, and miR-152) in serum of 36 non-small-cell lung carcinoma patients, 20 patients with benign pulmonary diseases, and 10 healthy individuals (PMID:25904302)
• miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNMT1 expression (PMID:25927928)
• findings define that miR-148b might play a critical role in maintenance of SP cells with CSC properties by targeting NRP1 in HCC. (PMID:25997710)
• miR148b directly targets Rhoassociated protein kinase 1 in hepatocellular carcinoma. (PMID:26530325)
• miR148b directly targeted mitogenactivated protein kinase (MAPK) kinase kinase 9 (MAP3K9), an upstream activator of MAPK kinase/cJun Nterminal kinase (JNK) signaling, suppressing the protein but not the mRNA levels. (PMID:26573018)
• Serum levels of the combined miRNA biomarkers, let-7b and miR-148b, appears to be a novel, reliable, and noninvasive test to predict the probability of having IgA nephropathy. (PMID:26581012)
• Data suggest that lower expression of microRNA-148b in lung of patients with non-small cell lung cancer (NSCLC) is positively associated with advanced tumor stage and radioresistance and predicts poor survival in patients with or without radiotherapy; thus, microRNA-148b may be an independent prognostic biomarker for NSCLC. (PMID:27083571)
• Our findings define an antagonistic relationship of miR-214 and miR-148b in determining the dissemination of cancer cells via tumor-endothelial cell interactions (PMID:27328731)
• Results suggest that overexpression of miR-148b protects against cervical cancer by inducing G1/S-phase cell cycle arrest and apoptosis through caspase-3-dependent manner. (PMID:27505047)
• Increase in muscle miR-148b content might thus participate in the decrease in insulin sensitivity at the whole body level during the transition toward physical inactivity. (PMID:27597765)
• miR-148b directly down-regulates renal megalin expression. (PMID:28331063)
• Taken together, our study provides a new perspective of miR-148b in gastric cancer (GC) development through inhibiting glycolysis in GC cells , directly targeting glucose transporter SLC2A1. (PMID:28440026)
• We further identified miR-148b as a negative regulator of proteasome beta-4 subunit. Enforced expression of miR-148b resulted in vitro growth inhibition of melanoma cells, whereas this inhibition was further abolished by enforced expression of proteasome beta-4 subunit (PMID:28656878)
• Studies suggest that miR-148/-152 family members (miR-148a, miR-148b and miR-152) might represent prognostic markers and/or potential therapeutic targets for treatment of autoimmune disorders, chronic inflammatory diseases and multiple types of cancer. (PMID:28880997)
• Targeting of Dock6 by miR-148b-3p could activate Rac1 and Cdc42, directly affecting the motility of GC cells. (PMID:29587866)
• MiR-148b-3p was shown to regulate KIT expression through directly binding to the 3’-UTR of the KIT mRNA. Restoration of miR-148b-3p expression in GIST882 cells led to reduced expression of KIT and the downstream effectors proteins ERK, AKT and STAT3. (PMID:29661252)
• Results find that miR-148b plays a critical role in promoting angiogenesis and that its inhibition promotes endothelial-to-mesenchymal transition process through regulation of TGF-beta pathway TGFB2 and SMAD2. (PMID:29843955)
• miR-148b-3p attenuates renal carcinoma cell growth, the invasion and tube formation of endothelial cell potentially via regulating FGF2-FGFR2 signaling pathway. (PMID:30099339)
• Therefore, downregulated miR-148b induced EMT of endometrial cancer cell as a result of relieving the suppression of DNMT1. Taken together, these results suggest that CAFs-mediated endometrial cancer progression is partially related to the loss of miR-148b in the exosomes of CAFs and promoting the transfer of stromal cell-derived miR-148b might be a potential treatment to prevent endometrial cancer progression (PMID:30146796)
• To examine the direct effects of the miRNAs on megalin and other membrane proteins expression, proximal tubule LLC-PK1 cells were transfected with miR-148b, miR-21, miR-146a, or miR-192 mimics. Transfection with miR-148b mimic, but not the other three miRNA mimics inhibited endogenous megalin mRNA expression. (PMID:30355654)
• Blood miR-151b level was negatively correlated with insulin-like growth factor-1 (IGF-1), and miR-27b-3p level was negatively correlated with IGF-1 and insulin-like growth factor binding protein-3, respectively. Our findings suggest that miR-148b-3p, miR-151b and miR-27b-3p may serve as blood-based biomarkers for diagnosing ischemic stroke patients, and the combination of miR-148b-3p and miR-27b-3p may be more powerful (PMID:30361294)
• These results demonstrate that miR-148b could inhibit the tumor growth and act as tumor suppressor by inhibiting the proliferation and inducing apoptosis of NSCLC cells by blocking the MAPK/JNK pathway. (PMID:30849960)
• MicroRNA-148b-3p is negatively regulated by long non-coding RNA H19. Both RNAs participate in hypoxia stress in human hepatic sinusoidal endothelial cells via positively regulating NOX4 and negatively regulating eNOS/NO signaling. (PMID:31082428)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	dre-mir-152	ENSDARG00000080838
danio_rerio	dre-mir-148	ENSDARG00000083365
mus_musculus	Mir148b	ENSMUSG00000065560
rattus_norvegicus	Mir148b	ENSRNOG00000035525

Paralogs (2): MIR148A (ENSG00000199085), MIR152 (ENSG00000207947)

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.